Teva Branded Pharmaceutical Products R&D LLC

This study is testing the long-term safety of an oral drug called Emrusolmin (TEV-56286) in 200 adults with multiple system atrophy (MSA), a rare and serious brain disorder. Participants who completed a prior trial will take the drug for about 100 weeks. The main goal is to see h…

This phase 3 trial tests a new inhaler that combines fluticasone (an anti-inflammatory) and albuterol (a fast-acting bronchodilator) for people 12 and older with asthma. Over 4 weeks, researchers will measure lung function and safety in 724 participants. The goal is to see if the…

This study tests an experimental oral drug, TEV-56286, in 350 adults with multiple system atrophy (MSA), a rare and progressive brain disorder. Participants will receive either the drug or a placebo for 48 weeks to see if it slows disease worsening and is safe. The goal is to fin…

This early-stage trial tests an experimental drug called TEV-56278, alone or with the immunotherapy pembrolizumab, in 240 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug…

This program provides fremanezumab, an injectable antibody that blocks a protein linked to migraine, to children aged 6 to 17 with chronic or episodic migraine. Participants must have completed a prior Teva-sponsored study. The goal is to see whether continued treatment can safel…

This early-stage trial tests the safety and how the body handles TEV-56286 (also known as emrusolmin or anle138b) in healthy adults. Participants receive either single or multiple rising doses of the drug or a placebo. The study measures how the drug is absorbed, distributed, and…